From: Immune related biomarkers for cancer metastasis to the brain
Primary Cancer | Pre-Treatment | Number of patients | Biomarker | Method | Sample type | Cut-off | HR | 95% CI | P value | Median follow-up (months) | Prognosis | References |
---|---|---|---|---|---|---|---|---|---|---|---|---|
SCLC | / | 32 | CD45RO + TIL | IHC | Tissue | sparse /scattered | NR | 0.000–26.14 | 0.007 | 11 | longer survival | [66] |
NSCLC | ICI | 25 | stromal CD8 + T | IHC | Tissue | Mean value of CD8 TIL infiltration | NR | NR | 0.031 | NR | longer survival | [74] |
Lung cancer | Surgery | 15 | CD8 + T cells | IHC | Tissue | 0.10% | NR | NR | NR | NR | longer survival | [34] |
Breast cancer | Surgery,STI, WBI | 89 | TIL | IHC | Tissue | 0.10% | NR | NR | 0.13 | 13 | longer survival | [64] |
Multiple cancers* | NIL | 26 | CD3 T-cell density | IHC | Tissue | Immunoreactive cells | NR | NR | 0.016 | 5.8 | longer survival | [68] |
Multiple cancers* | Surgery,STI, WBI | 223 | CD8 intratumoral expression | IHC | Tissue | 0.10% | NR | NR | 0.07 | 32 | NR | [69] |
Lung cancer | Surgery + TKI | 12 | TCR clonality | NGS | Tissue and blood | TCR clonality diversity | 0.175 | NR | p < 0.001 | NR | worse OS | [31] |
Lung carcinoma | Surgery | 33 | higher TCR clonality | NGS | Tissue and blood | higher TCR clonality | NR | NR | NR | NR | NR | [31] |
Lung carcinoma | Surgery | 33 | TPS | NGS | Tissue | Positive | 0.16 | NR | p = 0.001 | NR | NR | [31] |